MDS Pharma Services names Werner Weber, M.D., as director of operations, early clinical research, Hamburg
(May 7, 2001; Montreal, Canada) — MDS Pharma Services, one of the leading contract research organizations in the world, is pleased to announce the addition of Dr. Werner Weber to its staff as managing director, early clinical research, Hamburg, Germany. In this role, Dr. Weber will be responsible for all early clinical research operations in the Hamburg facility.
Dr. Weber possesses more than 15 years of clinical research experience. Prior to joining MDS Pharma Services, Dr. Weber served as director of Phases I-III clinical research for Biopharm, Berlin, and as senior study director for Parexel, Berlin. His background also includes several years with L.A.B. GmbH & Company, with whom he achieved the position of vice director, human pharmacology.
"With his experience, Dr. Weber will contribute significantly to the growth of our Hamburg facility and our European operations," said Terry Lenehan, vice president, clinical operations, Europe, MDS Pharma Services. "With his appointment, we continue to expand our early clinical research endeavors, an area in which our capabilities and expertise are simply unmatched."
Dr. Weber received his Approbation (medical degree) after completing studies in human medicine at the University of Ulm. His educational background also includes studies of chemistry and physics at the University of Munich.
As the global leader in early clinical research services, MDS Pharma Services offers extensive expertise in clinical pharmacology, bioequivalence, PK/PD analysis, data management and statistical services. Access to a large base of normal healthy participants and special populations ensures that studies start full and on-time. With seven clinical facilities and more than 625 beds, MDS Pharma Services intelligently applies advanced technology and expertise to develop seamless, successful early clinical studies.
MDS Pharma Services offers a full spectrum of resources to meet the drug discovery and development needs of the pharmaceutical and biotechnology industries. With facilities in more than 17 countries, the company applies advanced scientific and technological expertise to each stage of the drug discovery and development process: discovery, preclinical, early clinical research (Phase I-IIa), bioanalytical, global clinical research (Phase IIb-IV), and central lab.
MDS Pharma Services is a part of MDS Inc., an international health and life sciences company. The MDS focus is on using science to advance health, to fight disease. It does this by providing: laboratory testing, imaging agents for nuclear medicine testing, sterilization systems for medical and consumer products, research services to speed discovery and development of new drugs, therapy systems for planning and delivery of cancer treatment, analytical instruments to assist in the development of new drugs, and medical/surgical supplies. MDS employs more than 10,000 highly skilled people at its global operations on five continents. Detailed information about the company is available at www.mdsintl.com or by calling 1-888-MDS-7222, 24 hours a day.
